The Danish pharmaceutical group Novo Nordisk, the world’s leading insulin producer, reported a slightly worse than expected results for the first half and lowers the ceiling of its growth forecast for the full year.
Operating profit fell 6 percent to 24.8 billion Danish kronor, from 26.3 billion the first half of 2015. Analysts had on average expected an operating profit of 24.9 billion Danish crowns.
the sales increased by 5 percent to 54.7 billion Danish crowns, compared to 52.3 billion Danish kroner in the corresponding period last year.
Challenges in the US market driving prices down, according to the company, changing its growth forecast for 2016 to between 5 -7 percent from the previous 5-9 percent.
No comments:
Post a Comment